Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. 1995

M Zörnig, and A Grzeschiczek, and M B Kowalski, and K U Hartmann, and T Möröy
Institut für Molekularbiologie und Tumorforschung (IMT), Philipps Universität Marburg, Germany.

The Fas/Apo-1 receptor is an integral membrane protein that transduces apoptotic signals upon binding to its natural ligand or to specific antibodies. Loss of Fas/Apo-1 receptor leads in (lpr,lpr) mice to a nonmalignant accumulation of abnormal T-cells very probably due to the lack of induction of apoptosis in peripheral T-cells. It has been reported that soluble forms of Fas/Apo-1 receptor that may interfere with apoptotic signaling occur in patients suffering from various forms of lymphoid neoplasms. Therefore, we wished to investigate whether the loss of proper homeostatic regulation through Fas/Apo-1 receptor mediated apoptosis could influence the process of lymphomagenesis. To this end, we performed two experiments (i) we infected (lpr,lpr) animals with Moloney Murine Leukemia Virus (MoMuLV) that causes T-cell lymphoma in mice and (ii) we crossed (lpr,lpr) animals with E mu L-myc transgenic mice that are prone to develop T- and B-cell lymphoma due to deregulated expression of the L-myc transgene by the immunoglobulin enhancer E mu. We find that infection with MoMuLV did not accelerate the formation of lymphoid neoplasms in (lpr,lpr) mice when compared to infected normal animals. However, E mu L-myc/(lpr,lpr) animals that constitutively express the L-myc transgene in the lymphoid lineage clearly show accelerated formation of T- and B-cell lymphoma when compared to normal E mu L-myc transgenics. These data demonstrate that in cooperation with particular oncogenes impairment of Fas/Apo-1 receptor function can indeed affect and modulate the process of tumor formation.

UI MeSH Term Description Entries
D008808 Mice, Inbred CBA An inbred strain of mouse that is widely used in BIOMEDICAL RESEARCH. Mice, CBA,Mouse, CBA,Mouse, Inbred CBA,CBA Mice,CBA Mice, Inbred,CBA Mouse,CBA Mouse, Inbred,Inbred CBA Mice,Inbred CBA Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D008979 Moloney murine leukemia virus A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) arising during the propagation of S37 mouse sarcoma, and causing lymphoid leukemia in mice. It also infects rats and newborn hamsters. It is apparently transmitted to embryos in utero and to newborns through mother's milk. Moloney Leukemia Virus,Leukemia Virus, Moloney,Virus, Moloney Leukemia
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012192 Retroviridae Infections Virus diseases caused by the RETROVIRIDAE. Retrovirus Infections,Infections, Retroviridae,Infections, Retrovirus,XMRV Infection,Xenotropic MuLV-related Virus Infection,Xenotropic Murine Leukemia Virus-related Virus Infection,Infection, Retroviridae,Infection, Retrovirus,Infection, XMRV,Infections, XMRV,Retroviridae Infection,Retrovirus Infection,XMRV Infections,Xenotropic MuLV related Virus Infection,Xenotropic Murine Leukemia Virus related Virus Infection
D014412 Tumor Virus Infections Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses. Fibroma, Shope,Papilloma, Shope,Infections, Tumor Virus,Infection, Tumor Virus,Shope Fibroma,Shope Papilloma,Tumor Virus Infection
D015326 Gene Rearrangement, B-Lymphocyte, Heavy Chain Ordered rearrangement of B-lymphocyte variable gene regions of the IMMUNOGLOBULIN HEAVY CHAINS, thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the IMMATURE B-LYMPHOCYTES. B-Cell Heavy Chain Gene Rearrangement,B-Lymphocyte Heavy Chain Gene Rearrangement,B-Lymphocyte Mu Chain Gene Rearrangement,B Cell Heavy Chain Gene Rearrangement,B Cell Mu Chain Gene Rearrangement,B Lymphocyte Heavy Chain Gene Rearrangement,B Lymphocyte Mu Chain Gene Rearrangement
D015328 Gene Rearrangement, B-Lymphocyte, Light Chain Ordered rearrangement of B-lymphocyte variable gene regions coding for the kappa or lambda IMMUNOGLOBULIN LIGHT CHAINS, thereby contributing to antibody diversity. It occurs during the second stage of differentiation of the IMMATURE B-LYMPHOCYTES. B-Cell Light Chain Gene Rearrangement,B-Lymphocyte Light Chain Gene Rearrangement,B-Lymphocyte kappa-Chain Gene Rearrangement,B-Lymphocyte lambda-Chain Gene Rearrangement,B Cell Light Chain Gene Rearrangement,B Cell kappa-Chain Gene Rearrangement,B Cell lambda-Chain Gene Rearrangement,B Lymphocyte Light Chain Gene Rearrangement,B Cell kappa Chain Gene Rearrangement,B Cell lambda Chain Gene Rearrangement,B Lymphocyte kappa Chain Gene Rearrangement,B Lymphocyte lambda Chain Gene Rearrangement

Related Publications

M Zörnig, and A Grzeschiczek, and M B Kowalski, and K U Hartmann, and T Möröy
May 1989, Oncogene,
M Zörnig, and A Grzeschiczek, and M B Kowalski, and K U Hartmann, and T Möröy
May 1992, Oncogene,
M Zörnig, and A Grzeschiczek, and M B Kowalski, and K U Hartmann, and T Möröy
November 1995, Oncogene,
M Zörnig, and A Grzeschiczek, and M B Kowalski, and K U Hartmann, and T Möröy
May 1991, Cell,
M Zörnig, and A Grzeschiczek, and M B Kowalski, and K U Hartmann, and T Möröy
November 1991, Oncogene,
M Zörnig, and A Grzeschiczek, and M B Kowalski, and K U Hartmann, and T Möröy
February 1992, The Journal of experimental medicine,
M Zörnig, and A Grzeschiczek, and M B Kowalski, and K U Hartmann, and T Möröy
December 1989, Molecular biology & medicine,
M Zörnig, and A Grzeschiczek, and M B Kowalski, and K U Hartmann, and T Möröy
December 1999, Oncogene,
M Zörnig, and A Grzeschiczek, and M B Kowalski, and K U Hartmann, and T Möröy
April 1993, Cancer research,
M Zörnig, and A Grzeschiczek, and M B Kowalski, and K U Hartmann, and T Möröy
February 1996, Cytometry,
Copied contents to your clipboard!